Download Flash Player ►
Access Pharmaceuticals
accesspharma.com/index.shtmlProfil
Access Pharmaceuticals (ACCP: OTCBB) ist ein aufkommendes spezial-pharmazeutisches Unternehmen. Es entwickelt und kommerzialisiert Anstandsprodukte für die Behandlung und Betreuung von Krebspatienten. 'MuGard' (für oral mucositis) wird kommerziell in Europa eingesetzt und wird in den USA und in Asien in Q1, 2010 gründen. 'ProLindac', dass in klinischen Studien ist, ist eine neue und verbesserte Version von Sanofi-Aventis Eloxatin, ein DACH-Platin-Chemotherapie. 'Thiarabine' ist in Studien am Menschen zur Behandlung von Leukämien und Lymphomen. Access Pharmaceuticals hat auch Kooperationsabkommen abgeschlossen im Bereich Insulin und menschliche Wachstumshormone zur oralen Einnahme unter Verwendung der firmeneigenen Cobalamin(Vitamin B12)-basierten Verabreichungsmethode.
Aktienkurs
Aktuelle Nachrichten von Access Pharmaceuticals
- 11/12/2010 Access Pharmaceuticals wird $6,0m aufbringen
- 03/12/2010 Access Pharmaceuticals verbessert Mugard Website.
- 17/12/2009 Access Pharmaceuticals - Frank Jacobucci als Vizepräsident - verantwortlich für Verkauf und Marketing.
- 08/12/2009 Access Pharmaceuticals - MuGard für die Behandlung von oraler Mukositis
Vorstellungen
Verbundene Recherche
Keine Unterlagen verfügbar.
Unternehmensstrategie und – daten:
Access Pharmaceuticals is an emerging biopharmaceutical company specializing in products for cancer and supportive care. Access currently has one FDA-approved product, two products in Phase II clinical development, three products in preclinical development. Several of the company's products are based on Access' proprietary nanopolymer technologies which provide enhanced drug delivery options for both new and approved pharmaceutical active ingredients.
While its primary focus is in oncology, Access' drug delivery technologies also yield candidates that enable and enhance the absorption of drugs by exploiting the body's own vitamin B-12 absorption system.
Mucositis is a frequent side-effect of cancer therapy for which there is no established treatment. MuGard™ is Access' approved proprietary nanopolymer formulation for the management of mucositis. This ready–to–use rinse provides a soothing oral coating. A clinical study has shown that when MuGard is used by patients at the start of cancer therapy, the incidence and severity of mucositis are reduced. MuGard is available in Europe by prescription through Access' marketing partner, SpePharm. Access will be marketing MuGard in the United States in 2010, and marketing partners in Asia are advancing Regulatory approval of MuGard in South Korea and China.
Access is focusing its development effort on three products/technologies: ProLindac™, Thiarabine™, and Cobalamin™. The company's lead development candidate for the treatment of cancer is ProLindac™, a nanopolymer DACH platinum prodrug. ProLindac has successfully completed a European Phase II trial in patients with ovarian cancer, and Access and its Asian partners are planning to start Phase II combination studies shortly. Oxaliplatin (Eloxatin, Sanofi-Aventis) is the only DACH platinum currently approved; it has sales in excess of $2 billion.
Thiarabine™; is a Phase II nucleoside analog with considerable potential for treatment of lymphoma and leukemia. Extensive preclinical data shows that Thiarabine has good efficacy in a variety of tumor models.
Cobalamin™; is Access' proprietary nanopolymer oral drug delivery technology. Using a 'Trojan Horse' approach, the technology uses the body's natural vitamin B12 uptake mechanism in the gut to transport drugs that otherwise would have little or no oral bioavailability. The company is currently developing products for the oral delivery of insulin and human growth hormone (HGH), and is collaborating with a number of companies to develop additional formulations of various other pharmaceutically-active compounds.
Aktuelle Tätigkeiten:
MuGard
MuGard is a viscous, mucoadhesive rinse which provides a protective coating to the oral mucosa. In a comparison of patients undergoing standard care with patients using MuGard, the incidence and severity of mucositis was significantly lower for the MuGard group. MuGard has received marketing allowance in the United States under a 510(k) from the Food and Drug Administration.
For further information please
CLICK HERE
ProLindac
ProLindac is Access Pharmaceutical’s lead oncology drug, which has completed a phase 2 monotherapy study in ovarian cancer patients. It is a therapeutic, previously known as AP5346. It utilizes a safe, water-soluble nanoparticulate system to deliver DACH platinum (the active moiety of oxaliplatin) to tumors. Platinum-based drugs are among the largest classes of chemotherapeutics and oxaliplatin (Eloxatin; Sanofi-Aventis) is a DACH platinum drug that is projected to have had worldwide sales of over $2 billion in 2006.
The role of the Access’ nanoparticulate formulation of DACH platinum is to deliver more drug to the tumor while reducing delivery to normal tissue, thus increasing the drug’s effectiveness and decreasing the toxic side-effects. A major drawback of existing therapies is acute neurotoxicity. ProLindac has been shown to be much more effective than oxaliplatin in a large number of murine tumor models. In a phase 1 clinical study, at least five times more DACH platinum could be administered to patients with ProLindac than oxaliplatin. Moreover there was no indication in ProLindac of the acute neurotoxicity associated with oxaliplatin.
For further information please
CLICK HERE
Cobalamin™ -Mediated Oral Drug Delivery
Oral administration, by which pharmaceutically-active materials formulated as liquids, tablets or capsules are taken by mouth, remains by far the most prevalent method of drug delivery. It is also preferred by the vast majority of patients. However, its successful implementation requires that the active ingredient remains largely unaltered during transit through the gastrointestinal tract and that the drug possesses the requisite physico-chemical features (typically, low molecular weight, uncharged, and at least somewhat lipophilic) that allow it to pass readily across the wall of the intestine and be delivered into the bloodstream. For many active materials, particularly peptides and proteins, oral administration is currently not an option, as the level of uptake is less than one percent of the administered dose.
For further information please
CLICK HERE
Cobalamin™ -Mediated Disease Targeting
In many diseases which involve cell proliferation, there is increased demand for certain vitamins or vitamin analogs compared with normal tissue. Access Pharmaceuticals has developed technology which takes advantage of this increase in demand. By coupling drugs to Cobalamin™ (an analog of vitamin B12 or VB12), more drug is taken up by diseased cells. This effect can be amplified by attaching Cobalamin™ and several molecules of the drug to a polymer, or encapsulating the drug in a nanoparticle coated with Cobalamin. Access owns several patents and patent applications which provide the company with a proprietary position in amplified Cobalamin™-mediated targeted delivery of drugs to diseased cells.
For further information please
CLICK HERE
Thiarabine
Several nucleoside analogs are in routine clinical use for the treatment of cancer. Interest in the class of molecule remains high; three new nucleosides have received FDA approval with the past few years (cladribine, fludarabine, and gemcitabine). Nucleosides antimetabolites are effective in treating cancer because they are similar in structure to the natural nucleosides that are the building blocks of DNA and RNA. Cancer cells are ‘fooled’ into using these unnatural nucleosides for making DNA and/or RNA, resulting in chain termination and inhibition of DNA or RNA synthesis. Cell division is inhibited and ultimately tumor cell death occurs. Small changes in the structure of nucleosides can have a profound effect on the anticancer properties of these compounds, and there has been extensive research into nucleosides to produce compounds with improved activity.
For further information please
CLICK HERE
Management
Board of Directors
Steven H. Rouhandeh
Chairman
Chairman, SCO Financial Group LLC.
Mark Ahn, Ph.D.
Professor and Chair, Science & Technology Entrepreneurship, Victoria Management School,
University of Wellington, New Zealand
Mark J. Alvino
Managing Director, Griffin Securities, Inc.
Esteban Cvitkovic M.D.
Vice-Chairman (Europe)
Co-founder of OncoEthix
Jeffrey B. Davis
Chief Executive Officer
President, SCO Financial Group LLC.
Stephen B. Howell, M.D.
Professor of Medicine at University of California, San Diego, and Director
of Clinical Investigation and Development Therapeutics at UCSD Cancer Center
Senior Management
Jeffrey B. Davis
, President and Chief Executive Officer
Esteban Cvitkovic
, M.D., Vice Chairman, Senior Director, Clinical Oncology R&D
David P. Nowotnik
, Ph.D., Senior Vice President Research and Development
Stephen B. Thompson
, Vice President and CFO
Phillip Wise
, Vice President Business Development and Strategy
Frank Jacobucci,
Vice President of Sales and Marketing
For more information please click here
Hauptaktionäre
For up to date information on Access' news and share details please CLICK HERE
Kontakt
2600 Stemmons Freeway,
Suite 176
Dallas, TX 75207-2107
Tel: (214) 905-5100
Fax: (214) 905-5101
[email protected]
Unternehmensinformationen
Christine A. Berni
Director of Investor Relations
Tel: (212) 786-6208
[email protected]
Anleger, die in Access Pharmaceuticals interessiert sind, haben auch angesehen:
- ABM Resources (ASX: ABU)
- Algae.Tec (ASX: AEB)
- Allocate Software (AIM: ALL)
- Altus Strategies (AIM: Altus)
- Anglo Asian Mining (AIM: AAZ)
- Apella Resources Inc. (TSX-V: .APA)
- Arafura Resources (ASX: ARU)
- Argos Resources (AIM: ARG)
- ASX:BTV (ASX: BTV)
- Aura Energy Limited (ASX: AEE)
- Auzex Resources Limited (ASX: AZX)
- Avalon Rare Metals (TSX: AVL)
- Baobab Resources (AIM: BAO )
- Batavia Mining (ASX: BTV)
- Beowulf Mining plc (AIM: BEM)
- Cadillac Ventures, Inc (TSX-V: CDC)
- Camco (AIM: CAO )
- Central Petroleum (ASX: CTP)
- China Wind Systems (NASDAQ: CWS)
- Cockatoo Coal (ASX: COK)
- Condor Resources (AIM: CNR)
- Continental Coal (ASX: CCC)
- Copper Fox Metals (TSX-V: CUU)
- Deltex Medical Group plc (AIM: DEMG)
- Dragon Mining (ASX: DRA)
- Dragon Oil (LSE / ISE: DGO)
- e-Therapeutics plc (AIM: ETX)
- Eastmain Resources (TSX: ER)
- Eco Animal Health Group Plc (AIM: EAH)
- ECR Minerals (AIM: ECR)
- Elementos (ASX: ELT)
- Emmerson Resources (ASX: .ERM)
- Envirogold (ASX: EVG)
- Epistem (AIM: EHP)
- EurOmax Resources (TSX-V: EOX)
- Eurotin Inc. (TSX-V: ERT.P)
- Forte Energy (AIM / ASX: FTE)
- Genesis Resources (ASX: GES)
- Gowest Gold (TSX-V: GWA)
- Great Western Minerals Group (TSX-V: GWG)
- Greenearth Energy Ltd. (ASX: .GER)
- Greenscape Capital Group Inc (TSX-V: .GRN)
- Groote Resources (ASX: GOT)
- Gryphon Minerals (ASX: GRY)
- Gulf Resources (ASX: GLF)
- Halo Resources (TSX-V: HLO)
- Helius Energy Plc (AIM: HEGY)
- Icon Resources Limited (ASX: .III)
- IGas Energy Plc (AIM: IGAS)
- India Resources Ltd (ASX: IRL)
- Ironbark Zinc Limited (ASX: IBG)
- Ironclad Mining (ASX: IFE)
- IXR Resources (ASX: IXR)
- Jupiter Energy (ASX: JPR)
- Kalahari Resources Inc. (TSX-V: .KLA)
- Kentor Gold (ASX: KGL)
- Kiotech International (AIM: KIO)
- Knick Exploration (TSX-V: KNX)
- Legend Mining (ASX: LEG)
- Li3 Energy (OTCBB: LIEG)
- Lincoln Mining (TSX-V: LMG)
- Longwei Petroleum (NYSE: LPH)
- Medallion Resources (TSX-V: MDL)
- Metallica Minerals Ltd (ASX: .MLM)
- Millennium Minerals Limited (ASX: MOY)
- Millrock Resources (TSX-V: MRO)
- Mosquito Consolidated Gold Mines (TSX-V: MSQ)
- Mountain Lake Resources (TSX-V: MOA )
- Mutiny Gold (ASX: MYG)
- National Milk Records (PLUS: NMRP)
- Natural Resources USA Corporation (OTCBB: NTRC)
- NGM Resources (ASX: NGM)
- North River Resources (AIM: NRRP)
- NQ Exploration Inc (TSX-V: NQE)
- Ord River Resources Ltd (ASX: ORD)
- Orko Silver (TSX-V: OK)
- Ormonde Mining plc (AIM: ORM)
- Orosur Mining Inc. (AIM / TSX-V: OMI)
- Osceola Hydrocarbons (PLUS: OSCE)
- Ovoca Gold (AIM : OVG )
- Oxford Nutrascience (AIM: ONG)
- Peninsula Minerals (ASX: PEN)
- Petroceltic International (AIM: PCI)
- Planet Payment (AIM: PPT)
- Plato Gold Corp (TSX-V: PGC)
- Play LA Inc (NASDAQ OTC:BB: PLLAF)
- Prosperity Minerals Holdings Limited (AIM: PMHL)
- Pulse Health Limited (ASX: .PHG)
- Pure Energy (TSX-V: PEV)
- Ram Resources (ASX : RMR)
- Range Resources (AIM / ASX: RRL)
- Renovo Group Plc (LSE: RNVO)
- Resource Generation (ASX: RES)
- Rexahn Pharmaceuticals (AMEX: RNN)
- Rey Resources (ASX: .REY)
- Riverside Resources (TSX-V: RRI)
- Rodinia Minerals (TSX-V: .RM)
- SeaEnergy PLC (AIM: SEA)
- Selwyn Resources (TSX-V: .SWN)
- Shaw River Resources (ASX: SRR)
- Shree Minerals (ASX: SHH)
- Siburan Resources (ASX: SBU)
- Silver Lake Resources (ASX: SLR)
- Simba Energy (TSX-V: SMB)
- Solo Oil (AIM: SOLO)
- Specialist Energy Group (AIM: SEGR)
- St. Elias Mines (TSX-V: SLI)
- Stellar Resources (ASX: SRZ)
- Sumatra Copper & Gold (ASX: SUM)
- Sun Resources (ASX: SUR)
- Syndicated Metals (ASX: SMD)
- Tantalus Rare Earths (XETRA: TAE)
- Tarsis Resources (TSX-V: .TCC)
- Thor Mining (AIM / ASX: THR)
- Thundelarra Exploration (ASX: THX)
- Urals Energy (AIM: UEN)
- US Nickel (ASX: USN)
- Wessex Exploration (PLUS: WX.P)
- Westgold Resources Limited (ASX: WGR)
- YTC Resources (ASX: YTC)
